首页> European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)> 'Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update' (vol 94, pg 115, 2018)

'Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update' (vol 94, pg 115, 2018)

导出原文传递

翻译打印收藏纠错

第一作者： Choueiri, Toni K.

作者： Choueiri, Toni K. ^[1] ; Hessel, Colin ^[2] ; Halabi, Susan ^[3] ; Sanford, Ben ^[4] ; Michaelson, M. Dror ^[5] ; Hahn, Olwen ^[6] ; Walsh, Meghara ^[7] ; Olencki, Thomas ^[8] ; Picus, Joel ^[9] ; Small, Eric J. ^[10] ; Dakhil, Shaker ^[11] ; Feldman, Darren R. ^[12] ; Mangeshkar, Milan ; Scheffold, Christian ; George, Daniel ; Morris, Michael J.

作者单位： Exelixis Inc, San Francisco, CA USA ^[1] Duke Univ, Med Ctr, Duke Canc Inst, Durham, NC USA ^[2] Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO USA ^[3] Univ Kansas Wichita, Wichita, KS USA ^[4] Dana Farber Partners CancerCare, Boston, MA USA ^[5] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA ^[6] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA ^[7] Duke Univ, Alliance Stat & Data Ctr, Durham, NC USA ^[8] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA ^[9] Alliance Protocol Operat Off, Chicago, IL USA ^[10] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA ^[11] Duke Univ, Dept Biostat & Bioinformat, Durham, NC USA ^[12]

发布时间 2019-04-18

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交